CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | pCODR 10225 |
|---|---|
| Brand Name | Bavencio |
| Generic Name | Avelumab |
| Strength | 20 mg/mL |
| Tumour Type | Genitourinary |
| Indication | Urothelial Carcinoma (UC) |
| Funding Request | Bavencio is indicated for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy. |
| Review Status | Under Review |
| Pre Noc Submission | Yes |
| NOC Date | December 10, 2020 |
| Manufacturer | EMD Serono - Pfizer Alliance |
| Sponsor | EMD Serono - Pfizer Alliance |
| Submission Date | September 18, 2020 |
| Submission Deemed Complete | October 2, 2020 |
| Submission Type | New Indication |
| Prioritization Requested | |
| Stakeholder Input Deadline ‡ | October 2, 2020 |
| Check-point meeting | November 27, 2020 |
| pERC Meeting (target date) | February 18, 2021 |
| Initial Recommendation Issued (target date) | |
| Feedback Deadline (target date) ‡ | |
| Final Recommendation Issued (target date) | |
| Notification to Implement Issued |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.